| Clinical and Regulatory | |
|---|---|
| Event Type: | Phase 1/2 Results |
| Timing: | Q1 2017 |
| Designation(s): | Orphan Drug |
|
This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
|
|
| Disease and Treatment | |
|---|---|
| Disease: | Other |
| Indication: | Duchenne muscular dystrophy associated cardiomyopathy |
| Lead Indication?: | Yes |
| Treatment Name: | CAP-1002 |
|
Likelihood of event success varies depending on disease, treatment and lead indication classification.
|
|
| Company Information | |
|---|---|
| Co. Name: | Capricor Therapeutics |
| Stock Symbol: | CAPR |
| Shares Traded: | NASDAQ |
|
The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
|
|
| Event Status | |
|---|---|
| Event Outcome: | Ongoing |
| Event Discussion: | Forums |
| Event Announcement(s): | http://irdirect.net/pr/release/id/1821526 |
| Partnership: | No |
|
Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
|
|
Detailed Event Description from Company Announcement
QuoteWith heart disease being one of the primary drivers of death and disability in older DMD patients, each step we take toward better managing DMD is an important one. We look forward to sharing additional milestones from the HOPE-Duchenne trial in the coming months, including its top-line results, which are expected in the first quarter of 2017.